Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947–957.PubMedCrossRef 14. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S: Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 2010, 16:291–303.PubMedCrossRef 15. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S: EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment:
a systematic review and meta-analysis in non-small-cell Caspase Inhibitor VI manufacturer lung cancer. Ann Oncol 2011, 22:545–552.PubMedCrossRef 16. Sasaki H, et al.: Epidermal growth factor GSK1210151A chemical structure receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol 2008, 134:569–577.PubMedCrossRef 17. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al.: Assessment of somatic k-RAS
mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. The Lancet Oncology. 2008, 9:962–972.PubMedCrossRef 18. Pallis A, Briasoulis E, Linardou H, et al.: Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase ACP-196 inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Curr Med Chem 2011, 18:1613–1628.PubMedCrossRef Leukotriene-A4 hydrolase 19. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E: Histological typing of lung and pleural tumors. 3rd edition. Springer, Berlin; 1999.CrossRef 20. Murray S, Timotheadou E, Linardou H, et al.: Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 2006, 52:225–233.PubMedCrossRef 21. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P: Somatic mutations of the tyrosine kinase domain of epidermal growth
factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 2008, 3:832–839.PubMedCrossRef 22. Boldrini L, Gisfredi S, Ursino S, et al.: Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007, 2:1086–1090.PubMedCrossRef 23. Kislitsin D, Lerner A, Rennert G, Lev Z: K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for non homogeneous representation of mutation subtypes. Dig Dis Sci 2002, 47:1073–1079.PubMedCrossRef 24. Bamias A, Karina M, Papakostas P, et al.: A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010, 65:1009–1021.